Your shopping cart is currently empty

Clofarabine (Clofarex)m, a second generation purine nucleoside analog with antineoplastic activity, inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $36 | In Stock | In Stock | |
| 10 mg | $54 | In Stock | In Stock | |
| 25 mg | $87 | In Stock | In Stock | |
| 50 mg | $135 | In Stock | In Stock | |
| 100 mg | $175 | In Stock | In Stock | |
| 500 mg | $379 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
| Description | Clofarabine (Clofarex)m, a second generation purine nucleoside analog with antineoplastic activity, inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. |
| Targets&IC50 | Ribonucleotide reductase:65 nM |
| In vitro | In athymic nude mice or severe combined immunodeficient (SCID) mice, Clofarabine demonstrates inhibitory effects on various subcutaneously transplanted human tumor xenografts. |
| In vivo | In lymphocytes from chronic lymphocytic leukemia, 10 μM Clofarabine inhibits the repair induced by 4-hydroperoxycyclophosphamide with a peak inhibition at an intracellular concentration of 5 μM. Across a range of leukemia and solid tumor cell lines, Clofarabine demonstrates potent growth inhibition and cytotoxicity (IC50= 0.028–0.29 μM). |
| Synonyms | Evoltra, Clolar, Clofarex |
| Molecular Weight | 303.68 |
| Formula | C10H11ClFN5O3 |
| Cas No. | 123318-82-1 |
| Smiles | Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F |
| Relative Density. | 2.12 g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 245 mg/mL (806.77 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.59 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.